Target Name: RNF185
NCBI ID: G91445
Other Name(s): RNF185 variant 1 | RN185_HUMAN | BSK65-PANC2 | BSK65-TEST2 | BSK65-PANC1 | BSK65-MONO1 | BSK65-MONO2 | BSK65-TEST3 | ring finger protein 185 | E3 ubiquitin-protein ligase RNF185 | RING finger protein 185 | RING-type E3 ubiquitin transferase RNF185 | E3 ubiquitin-protein ligase RNF185 (isoform 1) | BSK65-TEST1 | Ring finger protein 185, transcript variant 1

Uncovering The Unique Properties of NF185: A RNA-DNA Hybrid with Potential as A Drug Target

RNA-Nucleic Acid-Protein (RNA-DNA) hybrids, also known as Ribonucleic Acid-Protein (RNA-Protein) hybrids, are a type of macromolecule that have been found in various organisms, including bacteria, archaea, and eukaryotes. These hybrids have a unique structure, as they contain both RNA and protein domains.

One of the most well-known RNA-DNA hybrids is called NF-kappa-Bp102, which is a 102-amino acid protein that is expressed in various tissues and cell types, including immune cells, neurons, and cardiac cells. The protein is composed of 115 amino acids that are encoded by the gene NF185.

NF185 is a non-coding RNA molecule that is expressed in a variety of cell types, including immune cells, epithelial cells, and neural cells. It is composed of a single exon that is located on the X chromosome. The RNA molecule is usually expressed in a polycombined form, which means that it is fused together with other RNA molecules to form a complex RNA structure.

One of the unique features of NF185 is its ability to interact with DNA. This interaction is critical for the function of the gene as it encodes a protein that is involved in a variety of cellular processes, including cell signaling, inflammation, and stress responses.

In addition to its role in gene expression, NF185 has also been shown to play a role in the regulation of cellular processes. For example, studies have shown that NF185 can interact with the protein Stat3, which is a transcription factor that is involved in cell signaling. This interaction between NF185 and Stat3 has been shown to play a role in the regulation of gene expression and cellular processes.

Another interesting property of NF185 is its ability to form a RNA-DNA hybrid. This hybrid has been shown to have unique properties that can be used for the development of new RNA-based therapeutics. For example, studies have shown that the NF185 RNA-DNA hybrid is able to be targeted to specific gene loci in the genome, which allows for the potential to target specific proteins with RNA-based therapeutics.

In addition to its potential as a drug target, NF185 has also been shown to have potential as a biomarker. The expression of NF185 has been shown to be elevated in a variety of cancer types, including breast cancer, lung cancer, and colorectal cancer. This suggests that NF185 may be a useful biomarker for the diagnosis and treatment of these diseases.

In conclusion, NF185 is a unique RNA-DNA hybrid that has been shown to play a variety of roles in cellular processes, including gene expression and cell signaling. Its ability to form a RNA-DNA hybrid and its potential as a drug target and biomarker make it an attractive target for further research and development. Further studies are needed to fully understand the functions of NF185 and its potential as a new drug or biomarker.

Protein Name: Ring Finger Protein 185

Functions: E3 ubiquitin-protein ligase that regulates selective mitochondrial autophagy by mediating 'Lys-63'-linked polyubiquitination of BNIP1 (PubMed:21931693). Acts in the endoplasmic reticulum (ER)-associated degradation (ERAD) pathway, which targets misfolded proteins that accumulate in the endoplasmic reticulum (ER) for ubiquitination and subsequent proteasome-mediated degradation (PubMed:27485036). Protects cells from ER stress-induced apoptosis (PubMed:27485036). Responsible for the cotranslational ubiquitination and degradation of CFTR in the ERAD pathway (PubMed:24019521). Also acts as a regulator of the innate antiviral response by catalyzing 'Lys-27'-linked polyubiquitination of CGAS at 'Lys-173' and 'Lys-384', thereby promoting CGAS cyclic GMP-AMP synthase activity (PubMed:28273161). Preferentially associates with the E2 enzymes UBE2J1 and UBE2J2 (PubMed:24019521)

More Common Targets

RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P | RNU1-4 | RNU1-42P | RNU1-55P | RNU1-61P | RNU1-63P | RNU1-72P | RNU1-73P | RNU1-78P | RNU1-7P | RNU1-82P | RNU1-88P | RNU105B | RNU11 | RNU12 | RNU2-1 | RNU2-17P | RNU2-2P | RNU2-4P | RNU2-54P | RNU2-5P | RNU2-6P | RNU4-1 | RNU4-14P | RNU4-2 | RNU4-30P | RNU4-33P | RNU4-38P | RNU4-39P | RNU4-46P | RNU4-53P | RNU4-62P